Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Statins are a cornerstone for managing dyslipidemia and preventing atherosclerotic cardiovascular disease (ASCVD).
• However, some patients experience adverse events, necessitating statin down-titration or discontinuation.
• Understanding the frequency of patients unable to continue statins is crucial for effective cardiovascular risk management.

Purpose of the Study:

• To determine the frequency of high-risk dyslipidemia patients unable to take or not taking statins for any reason.
• To assess the impact of statin intolerance on achieving target LDL-C levels.

Main Methods:

• Analysis of a Japanese hospital claims database from April 2008 to September 2017.
• Inclusion of 2,527,405 patients with dyslipidemia and ASCVD.
• Defined patient groups based on statin discontinuation, down-titration, non-statin lipid-modifying therapy (LMT) use, and muscle-related symptoms.

Main Results:

• Among patients prescribed statins, 2.32% (Definition 1) and 48.38% (Definition 2) were identified as unable to continue statins.
• 13.16% of eligible patients initiated non-statin LMT without prior statin use (Definition 3).
• Patients meeting these definitions showed lower achievement rates of target LDL-C levels compared to those who did not.

Conclusions:

• A notable proportion of high-risk dyslipidemia patients face challenges with statin therapy.
• Statin intolerance is linked to suboptimal LDL-C control and potentially increased residual cardiovascular risk.
• Alternative therapeutic strategies beyond current LMT are necessary for these patients.